Clinical trial
Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease
NCT00109291 · Affymax, Industry · Terminated
Key facts
| NCT number | NCT00109291 |
|---|---|
| Title | Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease |
| Official title | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Patients With Chronic Kidney Disease Who Are Not on Dialysis and Who Have Not Had Prior Erythropoiesis… |
| Lead sponsor | Affymax, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Chronic Kidney Disease, Chronic Renal Failure |
| Intervention type | Drug |
| Interventions | Placebo, peginesatide |
| Enrollment | 17 |
| Start date | Mar 1, 2005 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Apr 27, 2005 |
| Last update posted | Dec 21, 2012 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: